These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8622027)

  • 1. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.
    Lind MJ; Ghazal-Aswad S; Gumbrell L; Fishwick K; Craigs D; Millward MJ; Bailey NP; Dore-Green F; Chapman F; Simmons D; Proctor M; Oakey A; Robson L; Middleton I; McCann E; Sinha D; Calvert AH
    J Clin Oncol; 1996 Mar; 14(3):800-5. PubMed ID: 8622027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
    Belani CP; Aisner J; Hiponia D; Engstrom C
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study.
    Calvert AH; Lind MJ; Ghazal-Aswad S; Gumbrell L; Millward MJ; Bailey NP; Doré-Green F; Chapman F; Simmons D; Proctor M
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):1-6. PubMed ID: 7527590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study.
    Schilder RJ; Brady MF; Spriggs D; Shea T
    Gynecol Oncol; 2003 Jan; 88(1):3-8. PubMed ID: 12504619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of cisplatin i.p. and carboplatin i.v. with G-CSF in patients with ovarian cancer.
    Adachi S; Ito K; Itani Y; Noda T; Shintani M; Kawai S; Beppu K; Ito A; Saito K; Hisanaga H; Fukumoto Y; Tomii Y; Masuda M
    Oncol Rep; 1999; 6(2):311-5. PubMed ID: 10022995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel.
    Gordon AN; Hancock KC; Matthews CM; Stringer CA; Boston J; Nemunaitis J
    Am J Clin Oncol; 1999 Dec; 22(6):601-5. PubMed ID: 10597745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.
    Gore M; Mainwaring P; A'Hern R; MacFarlane V; Slevin M; Harper P; Osborne R; Mansi J; Blake P; Wiltshaw E; Shepherd J
    J Clin Oncol; 1998 Jul; 16(7):2426-34. PubMed ID: 9667260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.
    Hochster H; Speyer JL; Mandeli JP; Runowicz C; Wadler S; Berk G; Wallach R; Holland JF
    Gynecol Oncol; 1999 Mar; 72(3):292-7. PubMed ID: 10053098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
    Bookman MA; McGuire WP; Kilpatrick D; Keenan E; Hogan WM; Johnson SW; O'Dwyer P; Rowinsky E; Gallion HH; Ozols RF
    J Clin Oncol; 1996 Jun; 14(6):1895-902. PubMed ID: 8656258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.
    Weaver A; Wrigley E; Watson A; Chang J; Collins CD; Jenkins B; Gill C; Pettengell R; Dexter TM; Testa NG; Crowther D
    Br J Cancer; 1996 Dec; 74(11):1821-7. PubMed ID: 8956800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.
    Toner GC; Green M; Bishop JF; McKendrick J; Cebon J; Sheridan WP; Lockbaum P; O'Byrne J; Fox RM
    Am J Clin Oncol; 1998 Jun; 21(3):263-9. PubMed ID: 9626795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
    Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
    J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: a study of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
    Wils JA; van Geuns H; Wals J; Vreeswijk J; Lalisang F
    Anticancer Drugs; 1997 Jun; 8(5):432-5. PubMed ID: 9215604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
    Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
    J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.